BioSpace News Archive

Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the “Company”) is pleased to report financial results for the third quarter of fiscal 2021, the period ending October 31, 2020. All figures are reported in U.S. dollars.

SpringWorks Therapeutics, Inc. announced that Badreddin Edris, Ph.D., currently Chief Business Officer, has been promoted to Chief Operating Officer, and L. Mary Smith, Ph.D., currently Senior Vice President of Clinical Research and Development, has been promoted to Chief Development Officer.

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since October 2020.

Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel

-- Results further reinforce broad applications of company’s genetic toxicology assay in drug and chemical safety testing, mutational research, and in-human clinical uses --

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, today announced that the United States Patent and Trademark Office has issued a patent entitled “Anti-Nucleolin Agent-Conjugated Nanoparticles as Radio-Sensitizers an

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation, announced that more than 10,000 patients worldwide have been treated with the HeartLight® Endoscopic Ablation System.

M.S.Q. Ventures (“MSQ”) is pleased to announce that its client, ADC Therapeutics SA (NYSE: ADCT), has successfully entered into an agreement to jointly form a new company, Overland ADCT BioPharma (CY) Limited with Overland Pharmaceuticals, a fully integrated, biopharmaceutical company backed by Hillhouse Capital.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Ramelteon Tablets, 8 mg. Upsher-Smith’s product is AB-rated to the branded product, ROZEREM ® (ramelteon) tablets.* Ramelteon tablets are indicated for the treatment of insomnia characterized by difficulty with sleep onset.

Americans are nearly as worried about gaining weight between now and the end of the year (53%) as they are about not being able to see family for the holidays (54%)